Vertex Pharmaceuticals’ short interest has dropped by 22.32%, now sitting at 1.74% of its float—Wall Street seems less pessimistic. Short interest reflects how many shares are being bet against and ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.92% to $485.89 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to ...

In a series of recent legal challenges initiated by the pharmaceutical industry against the US Department of Health and Human Services Office of ...

Reshma Kewalramani’s journey to become the first female CEO of a large, public U.S. biotechnology company after immigrating ...

Zacks Research has upped the financial bar for Vertex Pharmaceuticals, boosting its 2026 earnings forecast from $16.18 to $16 ...

Global drugmakers and MedTech companies bounced back after U.S. President Donald Trump issued a 90-day pause on reciprocal ...

In a grueling season, Washington players know they can count on Anthony Gill. “I’m a servant. I love to be here for the guys in any way I can,” he said. Near the end of a challenging first ...

Capitol Hill Republicans, corporate America and White House allies are terrified about what’s next in Trump’s escalating ...

Keith Speights has positions in Bristol Myers Squibb, Pfizer, and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Bristol Myers Squibb, Pfizer, Regeneron Pharmaceuticals ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective increased by Bank of America from $555.00 to $567.00 in a research note issued on Monday,Benzinga reports.